[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Editor's Correspondence
May 09, 2011

Use of PPIs Are Not Associated With Mortality in Institutionalized Older People—Reply

Author Affiliations

Author Affiliations: Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, University of South Australia, Adelaide, Australia (Dr Bell); Department of Health Sciences/Geriatrics, University of Oulu, and Oulu City Hospital, Oulu, Finland (Dr Strandberg); and Unit of General Practice, Helsinki University Central Hospital, Helsinki, Finland (Dr Pitkälä).

Arch Intern Med. 2011;171(9):866-867. doi:10.1001/archinternmed.2011.165

In reply

We thank Wilson and colleagues for sharing their finding that baseline use of PPIs was not associated with 12-month mortality among 602 participants in a falls prevention study. As highlighted by Wilson and colleagues, prescribing practices and organization of care for older people often differ within and between countries. We agree that the specialized nature of our study cohorts limits extrapolation to other populations.

Twelve-month mortality among the residents of intermediate-level aged care facilities studied by Wilson and colleagues was 10.3% compared with 28.2% and 24.9% in our 2 cohorts.1 In addition to possible differences in organization of care, the lower mortality may attributed to the fact that residents were only eligible for inclusion in their falls prevention study if facility staff judged that they were likely to survive for 12 months.2 It is possible, therefore, that frail residents most susceptible to adverse drug events associated with PPIs were not included in the study.

First Page Preview View Large
First page PDF preview
First page PDF preview
×